<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01218399</url>
  </required_header>
  <id_info>
    <org_study_id>SU-10042010-7010</org_study_id>
    <secondary_id>IRB 15128</secondary_id>
    <nct_id>NCT01218399</nct_id>
  </id_info>
  <brief_title>Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations</brief_title>
  <official_title>A Randomized, Blinded, Single-center Study in Mild to Moderate Asthmatics Over the Age of 12 Years Who Have a Viral-mediated Exacerbation and Are Treated With Symbicort or Pulmicort Flexhaler</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an investigator-initiated study in which Dr. Nadeau wrote the protocol and received
      funding from an Astra Zeneca grant to direct, perform, and monitor the study on her own with
      Stanford staff. We hypothesize that the budesonide/formoterol combination improves the
      efficacy of budesonide alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was designed such that 30 participants would be consented/enrolled into the trial.
      The intervention would only be applied if the participant developed a viral illness that met
      eligibility criteria during the study period.

      Only 10 of the 30 ppt. consented/enrolled developed a virus and were then treated according
      to study arm.

      A more detailed description can be obtained by contacting Astra Zeneca
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>1 week</time_frame>
    <description>Asthma symptoms scores reported as measure of FEV1 - Forced Expiratory Volume in one second
FEV1 is given which is a standard outcome in asthma studies and is validated by the NIH (NHLBI)
FEV1 of less than 80 is indicative of severe asthma, 80-90 is moderate asthma, over 90 is mild asthma
http://www.med.umich.edu/1info/FHP/practiceguides/asthma/EPR-3_pocket_guide.pdf</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 week</time_frame>
    <description>Number of adverse events as per MEDRA terms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Budesonide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combination of budesonide and formoterol. Medications are given according to the package insert and manufacturer's instructions.
Participants that develop a viral upper respiratory illness which induces an asthma exacerbation.within the specified period following enrollment, are randomly assigned 1:1 to either study arm. 5 participants were randomly assigned to the Symbicort study arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator: Budesonide</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control of budesonide alone. Medication was given according to the package insert and manufacturer's instructions.
Participants that develop a viral upper respiratory illness which induces an asthma exacerbation.within the specified period following enrollment, are randomly assigned 1:1 to either study arm. 5 participants were randomly assigned to the Budesonide study arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort</intervention_name>
    <arm_group_label>Budesonide</arm_group_label>
    <arm_group_label>Placebo Comparator: Budesonide</arm_group_label>
    <other_name>Budesonide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects will be considered for inclusion in this study based on meeting all of the
        following criteria:

          1. Male or female, aged 12 to 65 years

          2. Subjects with mild to moderate asthma as determined by NHLBI 2007 guidelines

          3. Subjects with exacerbation of their asthma symptoms by NHLBI 2007 guidelines

          4. IgE level at study entry less than 50 IU/mL

          5. Men and women of reproductive potential who document use of adequate contraception
             during the study and for 3 months after the conclusion of treatment with study
             drug/placebo

          6. Historical documentation of asthma in the patient's medical record. The patient should
             have 6 months or more of asthma medication and management by a Stanford physician.

          7. Women of childbearing potential who have a negative pregnancy test (urine or serum) at
             the time of study entry

          8. Subject's guardians who are capable of understanding the purpose and risks of the
             study and who sign a statement of informed consent for the study

        Exclusion Criteria:

        Subjects will be ineligible for this study based on any one of the following criteria:

          1. With a chronic or acute disease that might interfere with the evaluation of Symbicort
             or Pulmicort Flexhaler therapy

          2. Pregnancy or lactation

          3. Current or prior malignancies (excluding non-melanoma skin carcinoma or carcinoma in
             situ of the cervix that has been adequately treated)

          4. History of infection with human immunodeficiency virus (HSC-1), hepatitis B virus
             (HBV), or hepatitis C virus (HCV); or Hepatitis A virus (HAV)

          5. Infections that require intravenous antibiotic therapy

          6. Significant organ dysfunction, including cardiac, renal, liver, CNS, pulmonary,
             vascular, gastrointestinal, endocrine, or metabolic (e.g., creatinine &gt;1.6 mg/dL; ALT
             or AST &gt; 1.5x the upper limit of normal; history of myocardial infarction, congestive
             heart failure, or arrhythmias within 6 months prior to study entry)

          7. Treatment with a humanized or chimeric antibody therapy within 4 weeks prior to study
             entry

          8. Treatment with any investigational drugs or therapies within 2 weeks prior to study
             entry

          9. Any use of oral, systemic corticosteroids within 2 weeks prior to study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kari Christine Nadeau</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2010</study_first_submitted>
  <study_first_submitted_qc>October 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2010</study_first_posted>
  <results_first_submitted>January 23, 2015</results_first_submitted>
  <results_first_submitted_qc>July 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 18, 2017</results_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Kari Christine Nadeau</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants that contract a viral upper respiratory illness which induces an asthma exacerbation and meets eligibility criteria will be randomized at Day 1 to either Symbicort or Budesonide in a 1:1 randomization. 5 participants were randomly assigned to the Symbicort study arm, and 5 participants were assigned to the Budesonide study arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Symbicort</title>
          <description>Combination of budesonide and formoterol
Symbicort will be given as per product insert (2 puffs twice daily of 160/4.5 Budesonide/formoterol)</description>
        </group>
        <group group_id="P2">
          <title>Budesonide</title>
          <description>Control of budesonide alone
Pulmicort Flexhaler will be given as per product insert (2 puffs twice daily of 160 mcg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Symbicort</title>
          <description>combination of budesonide and formoterol
Symbicort vs Budesonide in treating acute respiratory illness: use of either symbicort or budesonide</description>
        </group>
        <group group_id="B2">
          <title>Budesonide</title>
          <description>control of budesonide alone
Symbicort vs Budesonide in treating acute respiratory illness: use of either symbicort or budesonide</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" spread="5"/>
                    <measurement group_id="B2" value="25" spread="6"/>
                    <measurement group_id="B3" value="24" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Forced Expiratory Volume in One Second (FEV1)</title>
        <description>Asthma symptoms scores reported as measure of FEV1 - Forced Expiratory Volume in one second
FEV1 is given which is a standard outcome in asthma studies and is validated by the NIH (NHLBI)
FEV1 of less than 80 is indicative of severe asthma, 80-90 is moderate asthma, over 90 is mild asthma
http://www.med.umich.edu/1info/FHP/practiceguides/asthma/EPR-3_pocket_guide.pdf</description>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>combination of budesonide and formoterol
Symbicort vs Budesonide in treating acute respiratory illness: use of either symbicort or budesonide</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>control of budesonide alone
Symbicort vs Budesonide in treating acute respiratory illness: use of either symbicort or budesonide</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Forced Expiratory Volume in One Second (FEV1)</title>
          <description>Asthma symptoms scores reported as measure of FEV1 - Forced Expiratory Volume in one second
FEV1 is given which is a standard outcome in asthma studies and is validated by the NIH (NHLBI)
FEV1 of less than 80 is indicative of severe asthma, 80-90 is moderate asthma, over 90 is mild asthma
http://www.med.umich.edu/1info/FHP/practiceguides/asthma/EPR-3_pocket_guide.pdf</description>
          <units>% FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" spread="13"/>
                    <measurement group_id="O2" value="88" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Number of adverse events as per MEDRA terms</description>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>combination of budesonide and formoterol
Symbicort vs Budesonide in treating acute respiratory illness: use of either symbicort or budesonide</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>control of budesonide alone
Symbicort vs Budesonide in treating acute respiratory illness: use of either symbicort or budesonide</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Number of adverse events as per MEDRA terms</description>
          <units>Number adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data was collected for a year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Symbicort</title>
          <description>combination of budesonide and formoterol
Symbicort vs Budesonide in treating acute respiratory illness: use of either symbicort or budesonide</description>
        </group>
        <group group_id="E2">
          <title>Budesonide</title>
          <description>control of budesonide alone
Symbicort vs Budesonide in treating acute respiratory illness: use of either symbicort or budesonide</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Please contact the sponsor Astra Zeneca for the agreement</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elena Pizzi</name_or_title>
      <organization>Astra Zeneca</organization>
      <phone>+1 302 885 2677</phone>
      <email>Elena.Pizzi@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

